News for Reata Pharmaceuticals Stock (RETA)

Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering

GlobeNewsWire • 12/02/20

Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

GlobeNewsWire • 12/01/20

RETA LOSS ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

PRNewsWire • 12/01/20

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RETA

Newsfile Corp • 11/29/20

UPCOMING DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.– RETA

GlobeNewsWire • 11/27/20

RETA INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

GlobeNewsWire • 11/26/20

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Reata Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – RETA

GlobeNewsWire • 11/26/20

Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update

Zacks Investment Research • 11/25/20

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RETA

Newsfile Corp • 11/25/20

Reata Provides Update on Omaveloxolone Program for Patients with Friedreich's Ataxia

GlobeNewsWire • 11/24/20

Rosen, Global Investor Counsel, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETA

Newsfile Corp • 11/21/20

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 11/18/20

ROSEN, LEADING TRIAL ATTORNEYS, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETA

PRNewsWire • 11/18/20

ROSEN, A LEADING LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETA

Newsfile Corp • 11/13/20

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha • 11/09/20

Were Hedge Funds Wrong About Reata Pharmaceuticals, Inc. (RETA)?

Insider Monkey • 11/09/20

Recap: Reata Pharmaceuticals Q3 Earnings

Benzinga • 11/09/20

Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome

GlobeNewsWire • 11/09/20

Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

GlobeNewsWire • 11/09/20

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RETA

PRNewsWire • 11/04/20

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020

GlobeNewsWire • 11/02/20

RETA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Newsfile Corp • 10/30/20

ROSEN, A RESPECTED LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA

Business Wire • 10/28/20

Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich's Ataxia

GlobeNewsWire • 10/26/20

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA

Business Wire • 10/26/20